Adalvo acquires Enzene’s romiplostim biosimilar programme to strengthens global biosimilars push

Deal marks a strategic shift for Enzene towards a focused global CDMO business

Major TRANSFORM II trial finds sirolimus-coated balloon matches drug-eluting stents in coronary artery disease

One of the key findings was the low rate of bailout stenting in the SCB group

Wockhardt Q2 revenue jumps 24% to Rs 969 crore; H1 growth hits 25%

EBITDA for Q2 FY27 stood at Rs 165 crore, marginally higher than Rs 160 crore in Q2 FY26

Teva pulls plug on Phase 2 trial of experimental MSA drug post futility analysis

Emrusolmin is designed to target alpha-synuclein aggregation, a key disease mechanism believed to contribute to MSA

Granules India reports 39% surge in Q2 FY27 PAT to Rs. 182 Cr

Operational revenue grew 20.3% YoY to a record Rs. 1,560 crore

Zydus Wellness consolidated net sales up by 74.6% in Q2 FY27

Nutralite achieved robust, double-digit growth across its portfolio

Shilpa CDMO to invest $50 million in commercial peptide manufacturing

First commercial line comes online in December 2026 as CDMO scales capacity for GLP-1s and next-generation complex peptides

Sun Pharma Q2 net profit jumps to Rs 3,162 Cr; revenue rises 11.8% to Rs 16,100 Cr

Sun Pharma invested Rs 778.4 crore in research and development during the quarter, equivalent to 4.8% of sales

Spektus Pharma and GEBRO strike global deal to commercialise twice-daily pain drug ActraFlex

Under the agreement, the companies will divide global commercialisation responsibilities across key international markets

Scottish Secretary visits Agilus Diagnostics’ Mumbai lab to explores India collaboration on Rapid Microbial Testing

Thyrocare posts 25.1% revenue growth in Q2FY27

PAT jumps 25.7% to Rs 60.2 crore

CORONA Remedies Q2 FY27 revenue jumps 22% to Rs. 441 Cr

The impressive 22% growth rate significantly outpaces the broader Indian Pharmaceutical Market averages

Dr. Reddy’s bags tentative USFDA nod for twice-yearly HIV injectable lenacapavir across 120 nations

The approval was granted under the U.S. FDA’s President’s Emergency Plan for AIDS Relief (PEPFAR) program

Ind-Swift Laboratories’ Q2 FY27 revenue jumps 50% & operating EBITDA fivefold

The performance reflects the benefits of the company's strategic transition from an active pharmaceutical ingredients (API) manufacturer to a finished dosage formulations (FDF) player

RPG Life Sciences crosses Rs 200-crore quarterly revenue milestone as it posts 16.5% growth in Q2

The company's flagship brand, Naprosyn, also crossed the Rs 100-crore sales milestone, marking another significant achievement

Granules India’s Gagillapur facility completes USFDA inspection with 11 observations

The company confirmed that the USFDA observations do not involve data integrity or cross-contamination

Strong CDMO & healthcare performance lifts Piramal Pharma H1 revenue 23%

EBITDA surges 72%; Revenue growth outlook raised to 19-20%

Syngene posts 13% sequential revenue growth in Q2

Operating EBITDA rose to Rs 147 crore in Q2 FY27 from Rs 91 crore in the preceding quarter

Sanofi Consumer Healthcare India’s Q3 revenue rises 12% to Rs 263 Cr

Domestic sales grew 15% during the nine-month period

Zeus Hygia targets next wave of sports nutrition with CreaStab & CXR Energy